EGFR and colorectal carcinoma: Vidal et al [45] used OncoBEAMTM RAS CRC Kit to monitor RAS mutations in blood samples from mCRC patients during their anti-EGFR treatment, and found that RAS mutations in ctDNA mirrored the response to treatment.